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Leishmaniasis is a severe public-health problem, with high rates of morbidity andmortality. Efforts to ﬁnd
new, effective and safe oral agents for the treatment of leishmaniasis have been ongoing for several
decades, in order to avoid the problems with the currently used antimonials. In the present study, we
found that a copaiba oil oral treatment (Group IV) caused a signiﬁcant reduction in the average lesion
size (1.1 ± 0.4 mm) against Leishmania amazonensis lesions compared with untreated mice (Group I)
(4.4 ± 1.3 mm). To prove the safety of the oil, the toxicity and genotoxicity were also determined. Histopa-
thological evaluation did not reveal changes in the copaiba oil-treated animals compared to the control
animals. In the mutagenicity evaluation, (micronucleus test) the dose tested (2000 mg/kg) showed no
genotoxic effects. Morphological and ultrastructural analyses demonstrated notable changes in parasite
cells treatedwith this oleoresin. Themain ultrastructural effect wasmitochondrial swelling.We also dem-
onstrated that in vitro copaiba oil treatment of L. amazonensis led to an increase in plasma membrane per-
meability, and depolarization in the mitochondrial membrane potential in parasite cells. Although the
mechanism of action of the oleoresin is still unclear, these ﬁndings indicate that copaiba oil is a possible
new drug, which would provide a safer, shorter, less-expensive, and more easily administered treatment
for leishmaniasis.
 2011 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Leishmania is the protozoan parasite responsible for several
pathologies known collectively as leishmaniasis (McConville and
Handman, 2007). The worldwide prevalence is 12 million cases,
and the estimated population at risk is about 350 million in 88
countries on four continents. Currently, the estimated global
annual incidence of new cases is 2 million (Alvar et al., 2006). How-
ever, it is clear that ofﬁcial data frequently grossly underestimate
the reality, because leishmaniasis is not a notiﬁable disease in all
the countries where it is endemic. Therefore, a substantial number
of cases are never recorded (Bustamante et al., 2009).
The clinical manifestations of this infection depend on the spe-
cies of Leishmania and the immunological status of the host. The
disease can be classiﬁed as cutaneous leishmaniasis, mucocutane-
ous leishmaniasis, and visceral leishmaniasis, also known as Kala-
Azar (Clem, 2010). Leishmania amazonensis is a species that causes
cutaneous leishmaniasis (CL), which ranges from small cutaneousaduação em Microbiologia,
arcia Cid, PR 445, Km 380,
3011 5941.
ura).
evier OA license. nodules to gross mucosal tissue destruction (Reithinger et al.,
2007).
The pentavalent antimonial compounds have been used since
1940 to treat visceral and cutaneous leishmaniasis. Although new
drugs or drug formulations such as liposomal amphotericin B
(AmBisome), miltefosine, and paromomycin should be available
for treatment of leishmaniasis, they all have limitations of cost,
speciﬁc toxicities, or the need for parenteral administration (Lee
and Hasbun, 2003; Croft, 2008; Dujardin et al., 2010). Conse-
quently there is an urgent need to discover new drugs effective
against leishmaniasis.
The current use of herbal therapy in Leishmania-endemic
regions has renewed interest in evaluation of plant remedies used
in traditional medicine as sources of potential antileishmanials
(Iwu et al., 1994; Gachet et al., 2010; Tiuman et al., 2011). Interest-
ingly, the use of copaiba oils to treat leishmaniasis has been cited
in several ethnopharmacological studies with data obtained from
western Amazonia, in Peru (Kvist et al., 2006), eastern Amazonia,
in the state of Maranhão, Brazil (Moreira et al., 2002), and northern
Amazonia, in French Guiana (Fleury, 1997; Grenand and Moretti,
1987). Recently, Santos et al. (2008) reported that copaiba oils from
different species of Copaifera show activity against promastigote
forms of L. amazonensis. These results led us to investigate the
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together with in vitro studies by electron microscopy, biochemical
analysis, and ﬂow cytometry to determine the targets of copaiba oil
in L. amazonensis.2. Materials and methods
2.1. Copaiba oil
The copaiba oil was collected from the trunk of Copaifera martii
tree at Tapará, Pará (DC 349), and the sample was deposited in the
Herbarium Chico Mendes (Maricá, Rio de Janeiro). The chemical
characterization was performed by high-resolution gas chromatog-Fig. 1. Evaluation of cutaneous leishmaniasis development in mice treated with copai
untreated control; (C) Group II: The reference drug Glucantime (100 mg/kg/day) admini
by subcutaneous route; (G–I) Group V: Lesion treated topically with copaiba oil cream at
IV: copaiba oil emulsion at a dose of 100 mg/kg/day was administered orally by gavage. (M
also topical treatment with 4% copaiba oil cream applied on the lesions in an amount oraphy (HRGC) analyses with a Hewlett–Packard (HP) model 5890
instrument equipped with a ﬂame ionization detector as published
in Santos et al. (2008).2.2. Preparation of copaiba oil formulations
The available formulations were prepared as follows: The topical
cream (TE) was prepared using glycerin monostearate 6% (w/w),
stearic acid 2% (w/w), beeswax 1.5% (w/w), cetiol 11% (w/w), eth-
oxylated lanolin 1% (w/w), triethanolamine 1% (w/w), methyl para-
ben 0.18% (w/w), propyl paraben 0.2% (w/w) and distilledwater 50%
(w/w). Copaiba oil was added in tween 80 at the proportions of 1:1
and mixed until to uniformity. So, this mixture was added in theba oil. (A) Group VII: Uninfected and untreated control; (B) Group I: infected and
stered through intramuscular injection; (D–F) Group III: copaiba oil (100 mg/kg/day)
a concentration of 4%, applied on the lesions in an amount of 1 mg/mm2; (J–L) Group
–O) Group VI: The animals received oral treatment by gavage (100 mg/kg/day) and
f 1 mg/mm2.
Table 2
Micronucleus test – frequency of micronuclei in 2000 polychromatic erythrocytes
(MNPCE) in bone marrow of mice after 24 h of oral treatment with copaiba oil
(2000 mg copaiba oil/kg body weight – bw); positive control (cyclophospha-
mide = 40 mg/kg bw); and negative control (distilled water).
Treatment MNPCE (mean ± SD)
Copaiba oil 9.0 ± 1.4a
Cyclophosphamide 27.0 ± 4.0b
Distilled water 7.0 ± 1.8
MNPCE: micronucleated polychromatic erythrocytes; SD: standard deviation.
a No signiﬁcant difference when compared to negative control and signiﬁcant
difference when compared to positive control (ANOVA test; p < 0.05).
b Signiﬁcant difference when compared to negative control (ANOVA test;
p < 0.05).
Table 1
Effects of copaiba oil on lesion development in mice infected with L. amazonensis
promastigotes. Results are shown as the mean ± SD for the four mice in each group.
Treatment Average lesion size (mm) (mean ± SD)
Group I C(): Infected and untreated 4.4 ± 1.3
Group II (C+): Glucantime 0.9 ± 0.3a
Group III: C.O. Subcutaneous route 3.0 ± 1.0b
Group IV: C.O. Oral route 1.1 ± 0.4a
Group V: C.O. Topical 4.9 ± 0.3b
Group VI: C.O. Oral route and topical 1.2 ± 0.2a
C(): negative control; C(+): positive control; C.O.: copaiba oil; SD: standard
deviation.
a No signiﬁcant difference when compared to positive control and signiﬁcant
difference when compared to negative control (ANOVA test; p < 0.05).
b Signiﬁcant difference when compared to positive control (ANOVA test;
p < 0.05).
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cream.
For the oral formulation, the guar gum at concentration of 5%
(w/w) was dispersed in water under stirring for 4 h. After, the
remaining water and 5% (w/w) of tween 80 were added in order
to complete the homogeneous polymer dispersion. The copaiba
oil was mixed in tween 80 at proportion of 1:1 and added in the
preparation in order to obtain the oral emulsion (OE). The oral dose
of copaiba oil was 100 mg for kg of the evaluated animal. The intra-
muscular preparations were obtained by the mixture of copaiba oil
in tween and PBS at proportions of 1:1:1.
2.3. Parasites
The promastigote forms of L. amazonensis (MHOM/BR/75/Jose-
fa) were isolated from a human case of diffuse cutaneous leish-
maniasis. This strain has been maintained by weekly transfers in
Warren’s medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS) at 25 C in a tissue ﬂask. The infective promas-
tigote was maintained by inoculation into the footpads of BALB/c
mouse every 4–6 weeks. After development of lesion, we per-
formed the excised of lesions and the isolation of L. amazonensis.
The infective promastigotes were cultured in Warren’s medium
supplemented with 20% FBS, penicillin (100 U/ml), and streptomy-
cin (0.1 mg/ml) at 28 C. They were then used in the stationary
phase of growth (day 6 of culture). Axenic amastigote forms were
obtained as described by Ueda-Nakamura et al. (2001).
2.4. Animals
Male BALB/c mice between 4 and 6 weeks of age (20–25 g) and
male and female (8–12 weeks)Mus musculus (Swiss) outbred mice,
weighing 25–30 g were obtained from Universidade Estadual de
Maringá (UEM, PR, Brazil). All animals were acclimatized to our
laboratory conditions for 10 days before the beginning of the
experiments. Animals were under standard laboratory conditions
on a constant 12 h light/dark cycle with controlled temperature
(22 ± 2 C). Food (Nuvilab Cr1) and water were given ad libitum.
The Institutional Ethics Committee of Universidade Estadual de
Maringá approved all procedures adopted in this study (Protocol
013/2010).
2.5. Infection of animals
BALB/c mice were divided into seven groups that consisted of at
least 4 BALB/c mouse. Each mouse was inoculated subcutaneously
with 1  107 metacyclic promastigotes using 27.5-gauge needle
with a volume of 25 ll PBS into the left rear footpad of the mice.
Lesion development was monitored weekly by measuring of the
thickness of the infected footpad with a calliper (DIGIMESS
150 mm) for a total period of 8 weeks. The treatments were started
after development of lesions (30 days pos-infection) and continued
for 4 weeks. Lesion size was expressed as the difference in thick-
ness between parasite-inoculated footpad and the contralateral
footpad of the same animal.
2.6. Treatments of infected animals and histological studies
The groups were distributed as follows: Group I: infected and
untreated control; Group II: The reference drug Glucantime
(100 mg/kg/day) was dissolved in PBS and administered through
intramuscular injection. Group III: copaiba oil (100 mg/kg/day)
by subcutaneous route was made up in solution of Tween and
PBS; Group IV: copaiba oil emulsion at a dose of 100 mg/kg/day
was administered orally by gavage. The oil was suspended in
Tween (Sigma Chemical Co. USA) and diluted in 5% Goma-Guar.Group V: Lesion received topical treatment. The copaiba oil cream
at concentration of 4% was applied on the lesions in an amount of
1 mg/mm2. Group VI: The animals received oral treatment by ga-
vage (100 mg/kg/day) and also topical treatment with copaiba oil
cream 4% being applied on the lesions in an amount of 1 mg/
mm2. Group VII: Uninfected and untreated control. The solutions
were made up daily. All treatments were realized by 30 days after
development of lesion. At the end of the 30-day-treatment period
the animals were killed in a CO2 chamber. Some selected organs
(esophagus, stomach, duodenum, heart, kidney, liver, spleen, lung,
and testiculum) were removed and processed for histological stud-
ies. Thus, the organs were ﬁxed in Bouin’ ﬂuid, embedded in paraf-
ﬁn wax. Blocks were sectioned at 7 lm thickness in a microtome
(Leica Microsystems Inc, Germany), mounted in a electrostatic
slides and stained with hematoxylin-eosin.2.7. Micronucleus test
Ten-animal groups (Mus musculus ﬁve males and ﬁve females)
were treated orally by gavage with 2000 mg copaiba oil/kg body
weight (bw), and were killed 24 h after the copaiba oil administra-
tion. The positive control (cyclophosphamide = 40 mg/kg bw) and
negative control (distilled water) groups were also included (Costa
et al., 2010). After the treatment periods, the femurs were exposed
and sectioned, and the bone marrow was gently ﬂushed out using
fetal calf serum. After centrifugation (3000g, 5 min) the bone mar-
row cells were smeared on glass slides, coded for blind analysis, and
air-dried. The smears were stained with May-Grunwald-Giemsa to
detect micronucleated polychromatic erythrocytes (MNPCE) (Sch-
mid, 1975). For each animal, three slides were prepared and 2000
polychromatic erythrocytes (PCE – polychromatic erythrocytes)
were counted to determine the frequency of MNPCE. The slides
were analyzed with the use of an Olympus BH-2 microscope
(1000).
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microscopy
Promastigote forms were treated with copaiba oil obtained
from C. martii and then processed for scanning and transmission
electron microscopy as described previously in Santos et al. (2008).2.9. Flow cytometry
L. amazonensis axenic amastigotes (5  106 parasites/mL) were
treated with copaiba oil from C. martii (100 lg/mL for 3 h at
32 C), or untreated. After that were harvested and washed with
PBS. The integrity of the plasma membrane was assessed by the
entrance of the propidium iodide (PI) (20 lg/mL for 5 min). ToFig. 2. Scanning electron micrographs of promastigote forms of L. amazonensis treated wi
of copaiba oil; (C and D) Promastigotes after treatment with IC90 of copaiba oil (Bars = 1
copaiba oil stained with propidium iodide (PI) (D) Untreated cells; (F) Amphotericin-B; (G
numbers in bold show the percentage of PI-stained positive cells in the upper left quadanalyses of mitochondrial membrane potential (DWm) parasites
were stained with Rhodamine 123 (Rh 123) (5 mg/mL for 30 min
at 37 C) reagents. The compounds Amphotericin B (5 lM) and,
Carbonyl Cyanide m-chlorophenylhydrazone (CCCP) (200 lM)
were used as a positive control. The material was kept on ice until
analysis. The mean of ﬂuorescence intensity of the cells were ana-
lyzed by ﬂow cytometry FACSCalibur and CellQuest software. A to-
tal of 10,000 events were acquired in the region previously
established as that corresponding to the parasites.2.10. Statistical analysis
Data are presented as mean ± SD. The statistical signiﬁcance of
differences in percentage between treated and untreated was ana-th copaiba oil (A) Promastigotes, control; (B) Promastigotes after treatment with IC50
lm) and ﬂow cytometry analysis of L. amazonensis axenic amastigotes treated with
) Amastigotes treated with 100 lg/mL; (H) Amastigotes treated with 200 lg/mL. The
rant.
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Anova one-way test followed by Dunnet test. Differences were
considered signiﬁcant at p value of less than 0.05.3. Results and discussion
There is no single optimal treatment for cutaneous leishmania-
sis (Hepburn, 2000; Markle and Makhoul, 2004; Palumbo, 2010).
Natural products have made and are continuing to make important
contributions to the search for new antileishmanial drugs (Tiuman
et al., 2005; Khaliq et al., 2009; Singh et al., 2009; Vendrametto
et al., 2010). Recently, Santos et al. (2008) reported that copaiba
oils from different species of Copaifera show activity against pro-
mastigote forms of L. amazonensis. Taken together, these facts
encouraged us to evaluate the treatment of experimentally in-
fected animals with copaiba oil. For the in vivo tests, BALB/c mice
were infected subcutaneously with L. amazonensis (1  107 cells/
ml) in the left rear footpad. The treatment was started on the 4th
week post-infection. Mice were treated subcutaneously (Group
III), orally (Group IV), topically (Group V), or orally and topicallyFig. 3. Ultrastructural effect of copaiba oil on promastigote forms of L. amazonensis.
Promastigote treated with IC90 of copaiba oil; The treatment with copaiba oil led to c
appearance of concentric membrane structures inside the organelle (arrow). n, nucleus; f
Cytometry analysis of Rh123-labeled axenic amastigotes of L. amazonensis. (D) Untreated
treated with 200 lg/mL. The numbers in bold represent the percentage of collapsed DW(Group VI). Treatment with Glucantime (Group II) was used as a
positive control. The lesion size was measured with a caliper each
week for one month of infection. Fig. 1 and Table 1 present the re-
sults of the treatments. Interestingly, the oral treatment (Fig. 1J, K,
and L), and the oral and topical treatments (Fig. 1M, N, and O)
caused signiﬁcant (p < 0.05) reductions in the average lesion size
(1.1 ± 0.4 mm), and (1.2 ± 0.2 mm) compared with untreated mice
(Group I) (4.4 ± 1.3 mm) (Fig. 1B), and showed no signiﬁcant differ-
ence compared to the positive control Glucantime (Fig. 1C)
(0.9 ± 1.3 mm). The topical (Fig. 1G, H, and I) (4.9 ± 0.3 mm) and
subcutaneous (Fig. 1D and F) (3.0 ± 1.0 mm) treatments showed
no signiﬁcant reduction in the average lesion size (p < 0.05). More-
over, the subcutaneous treatment caused injuries in the animals
during the applications, as shown in Fig. 1G.
The main chemical constituents of C. martii are sesquiterpenes
(37.7%) and diterpenes (62.3%). The most common sesquiterpenes
are b-bisabolene (10.7%) and a-zingiberene (7.2%). Kaurenoic
(7.9%) and kovalenic (29.0%) acids are the main diterpenes (Santos
et al., 2008). Several reports have demonstrated that the biological
effect of copaiba oils may be explained by the complex nature of
these sesquiterpene and diterpene mixtures, which might affect(A) Promastigote control; (B) Promastigote treated with IC50 of copaiba oil; (C)
hanges in the mitochondria (m) including mitochondrial swelling (stars) and the
, ﬂagellum; fp, ﬂagellar pocket; k, kinetoplast; m, mitochondrion. Bars = 1 lm. Flow
cells; (E) CCCP 200 lM; (F), Amastigotes treated with 100 lg/mL; (G) Amastigotes
m cells in the upper right quadrant.
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itas, 2007). Lima et al. (2003) reported that fractionation of copaiba
oils results in fractions that are less active than the crude copaiba
oil.
An important criterion in the search of active compounds with
antiprotozoal activity is their toxicity to mammalian host cells. For
this purpose, the toxicity and genotoxicity of the copaiba oil were
determined. Histopathological evaluation did not reveal changes in
the esophagus, stomach, duodenum, heart, kidney, liver, spleen,
lung, or testicles of animals treated with copaiba oil compared to
control animals. No clinical or behavioral changes were observed
in the animals treated with the oleoresin. In the mutagenicity eval-
uation, the dose tested (Schmid, 1975) showed no genotoxic ef-
fects. The copaiba oil dose of 2000 mg/kg showed a frequency of
MNPCE of 9.0 ± 1.4 (Mean ± SD) in 2000 polychromatic erythro-
cytes. These levels were signiﬁcantly lower than the positive con-
trol (27.0 ± 4.0), and did not differ from the negative control
(7.0 ± 1.8) (Table 2). However, are still further testing is needed
to prove the total absence of genotoxicity.
To investigatewhich organellesmight be the initial targets of co-
paiba oil, SEM and TEM techniques were employed. Figs. 2 and 3
showmorphological alterations in promastigotes treated with con-
centrations corresponding to the IC50 (14.0 lg/mL) and IC90
(70.0 lg/mL) values of copaiba oil. Untreated control promastigotes
(Fig. 2A) showed the typical elongated shape. In contrast, the para-
sites treated with copaiba oil showed notable morphological
changes, such as the appearance of aberrant-shaped cells (Fig. 2B–
D). Ultrastructural changes in promastigotes treated with copaiba
are illustrated in Fig. 3. Untreated promastigotes showed no plasma
membrane alterations, and organelles with normal morphology
(Fig. 3A). The most prominent effects observed in treated parasites
were swollen mitochondria in all the treated cells (Fig. 3B and C).
To improve drug therapies for leishmanial infections and for the
development of new drugs, it is necessary to identify the targets of
parasite cells that have the potential to be safe and effective treat-
ments. The cell viability of axenic amastigotes of L. amazonensis
was checked by staining the cells with propidium iodide (PI), a
ﬂuorescent dye that binds speciﬁcally to DNA. As shown in Fig. 2,
the gated percentage (upper-left quadrant) of PI-stained cells after
treatment with copaiba oil (44.25% in parasites treated with
100 lg/mL and 48.9% treated with 200 lg/mL) (Fig. 2G and H)
was higher than the number in non-treated parasites (6.25%
Fig. 2E) and similar to the positive control treated with Amphoter-
icin B (76.67%, treated with 5 lg/mL) (Fig. 2F). All treatments were
administered for 3 h at 32 C. These data might indicate that copai-
ba oil induces in axenic amastigotes a considerable increase in
plasma membrane permeability. This is in agreement with the
observations of Santa-Rita et al. (2004) who demonstrated that
treatment with edelfosine at concentrations above 1 mM in PBS
for 10 min led to a gradual increase in membrane permeability.
The mitochondrial transmembrane potential was investigated
by using the ﬂuorescent probe Rh 123, which accumulates within
energized mitochondria, in conjunction with ﬂow cytometry anal-
ysis. Data obtained showed a marked decrease in the percentage
population of the upper right gated (17.75% and 20.12%), indicating
depolarization of the mitochondrial membrane potential in the
cells following treatment with copaiba oil at 100 lg/mL and
200 lg/mL, respectively (Fig. 3F and G). Similarly, a decrease in
membrane potentials was also observed following treatment with
the standard drug Carbonyl Cyanide m-chlorophenylhydrazone
(CCCP) (39.37%) at 200 lM for 3 h at 32 C (Fig. 3E). In contrast, un-
treated cells maintained the membrane potential (92.82%)
(Fig. 3D). Several antileishmanial drugs have produced a depolar-
ization in the mitochondrial membrane potential. Investigations
of the mitochondrial potential have reported that a main func-
tional impact of mitochondrial alterations is programmed celldeath by apoptosis (Singh et al., 2009; Santa-Rita et al., 2006;
Sen et al., 2007; Misra et al., 2008; Kaur et al., 2010).
Copaiba oil from C. martii was identiﬁed as an orally active
antileishmanial drug, through evaluation of BALB/c mice infected
with L. amazonensis. Exposure of the parasites to copaiba oil in-
duces an increase in plasma membrane permeability, and depolar-
ization in the mitochondrial membrane potential. Although the
mechanism of action of the oleoresin is still unclear, these ﬁndings
indicate that copaiba oil might be a new drug, which would consti-
tute a safer, shorter, less-expensive, and more easily administered
treatment for leishmaniasis. Given the promising results obtained
with copaiba oil (oral treatment) our next goals are to test new oral
formulations containing copaiba oil, and to verify the effects of
these oral formulations distribution (different sites of infection),
providing an evidence about the pathologic lesion pre-and post-
treatment, immuno-modulators studies, and tests of acute and
chronic toxicity to provide information about the safety of the
use of copaiba oil.
Acknowledgments
This study was supported through grants from Conselho Nac-
ional de Desenvolvimento Cientíﬁco e Tecnológico (CNPq), Financi-
adora de Estudos e Projetos (FINEP), Programa de Núcleo de
Excelência (PRONEX/Fundacão Araucária).
References
Alvar, J., Yactayo, S., Bern, C., 2006. Leishmaniasis and poverty. Trends in
Parasitology 2, 552–557.
Bustamante, M.C., Pereira, M.J., Schubach, A.O., da Fonseca, A.H., 2009.
Epidemiological proﬁle of cutaneous leishmaniasis in an endemic region in
the State of Rio de Janeiro, Brazil. Revista Brasileira de Parasitologia Veterinária
18, 34–40.
Clem, A., 2010. A current perspective on leishmaniasis. Journal of Global Infectious
Diseases 2, 124–126.
Costa, M.A., Ishida, K., Kaplum, V., Koslyk, E.D., de Mello, J.C., Ueda-Nakamura, T.,
Dias-Filho, B.P., Nakamura, C.V., 2010. Safety evaluation of proanthocyanidin
polymer-rich fraction obtained from stem bark of Stryphnodendron adstringens
(BARBATIMAO) for use as a pharmacological agent. Regulatory Toxicology and
Pharmacology 58, 330–335.
Croft, S.L., 2008. Kinetoplastida: new therapeutic strategies. Parasite 15, 522–527.
Dujardin, J.C., Gonzalez-Pacanowska, D., Croft, S.L., Olesen, O.F., Spath, G.F., 2010.
Collaborative actions in antitrypanosomatid chemotherapy with partners from
disease endemic areas. Trends in Parasitology 26, 395–403.
Fernandes, F.F., Freitas, E.P.S., 2007. Acaricidal activity of an oleoresinous extract
from Copaifera reticulata (Leguminosae: Caesalpinioideae) against larvae of the
southern cattle tick, Rhipicephalus (Boophilus) microplus (Acari: Ixodidae).
Veterinary Parasitology 147, 150–154.
Fleury, M., 1997. A propos de l’intérêt médicinal du baume de Copahu. Acta
Botanica Gallica 144, 473–479.
Gachet, M.S., Lecaro, J.S., Kaiser, M., Brun, R., Navarrete, H., Muñoz, R.A., 2010.
Assessment of anti-protozoal activity of plants traditionally used in Ecuador in
the treatment of leishmaniasis. Journal of Ethnopharmacology 2, 184–197.
Grenand, P., Moretti, C., 1987. Pharmacopées traditionnelles en Guyane. Créoles
Palikur, Wayãpi: Orstom, Paris, 569.
Hepburn, N.C., 2000. Cutaneous leishmaniasis. Clinical and Experimental
Dermatology 25, 363–370.
Iwu, M.M., Jackson, J.E., Schuster, B.G., 1994. Medicinal plants in the ﬁght against
leishmaniasis. Parasitology Today 10, 65–68.
Kaur, J., Singh, N., Singh, B.K., Dube, A., Tripathi, R.P., Singh, P., Singh, N., 2010.
Leishmania donovani: oral therapy with glycosyl 1,4-dihydropyridine analogue
showing apoptosis like phenotypes targeting pteridine reductase 1 in
intracellular amastigotes. Experimental Parasitology 125, 310–314.
Khaliq, T., Misra, P., Gupta, S., Reddy, K.P., Kant, R., Maulik, P.R., Dube, A., Narender,
T., 2009. Peganine hydrochloride dihydrate an orally active antileishmanial
agent. Bioorganic & Medicinal Chemistry Letters 1, 2585–2586.
Kvist, L.P., Christensen, S.B., Rasmussen, H.B., Mejia, K., Gonzalez, A., 2006.
Identiﬁcation and evaluation of Peruvian plants used to treat malaria and
leishmaniasis. Journal of Ethnopharmacology 106, 390–402.
Lee, S.A., Hasbun, R., 2003. Therapy of cutaneous leishmaniasis. International
Journal of Infectious Diseases 7, 86–93.
Lima, S.R.M., Veiga-Junior, V.F., Christo, H.B., Pinto, A.C., Fernandes, P.D., 2003. In
vivo and in vitro studies on the anticancer activity of Copaifera multijuga Hayne
and its fractions. Phytotherapy Research 17, 1048–1053.
Markle, W.H., Makhoul, K., 2004. Cutaneous leishmaniasis: recognition and
treatment. American Family Physician 15, 1455–1460.
A.O. dos Santos et al. / Experimental Parasitology 129 (2011) 145–151 151McConville, M.J., Handman, E., 2007. The molecular basis of Leishmania
pathogenesis. International Journal for Parasitology 37, 1047–1051.
Misra, P., Khaliq, T., Dixit, A., Sen Gupta, S., Samant, M., Kumari, S., Kumar, A.,
Kushawaha, P.K., Majumder, H.K., Saxena, A.K., Narender, T., Dube, A., 2008.
Antileishmanial activity mediated by apoptosis and structure-based target
study of peganine hydrochloride dihydrate: an approach for rational drug
design. Journal of Antimicrobial Chemotherapy 62, 998–1002.
Moreira, R.C., Rebelo, J.M., Gama, M.E., Costa, J.M., 2002. Knowledge level about of
American tegumentary leishmaniasis (ATL) and use of alternative therapies in
an endemic area in the Amazon Region in the State of Maranhão, Brazil.
Cadernos de Saúde Pública 18, 187–195.
Palumbo, E., 2010. Treatment strategies for mucocutaneous leishmaniasis. Journal
of Global Infectious Diseases 2, 147–150.
Reithinger, R., Dujardin, J.C., Louzir, H., Pirmez, C., Alexander, B., Brooker, S., 2007.
Cutaneous leishmaniasis. The Lancet Infectious Diseases 7, 581–596.
Santa-Rita, R.M., Henriques-Pons, A., Barbosa, H.S., Castro, S.L., 2004. Effect of the
lysophospholipid analogues edelfosine, ilmofosine and miltefosine against
Leishmania amazonensis. Journal of Antimicrobial Chemotherapy 54, 704–710.
Santa-Rita, R.M., Barbosa, H.S., de Castro, S.L., 2006. Ultrastructural analysis of
edelfosine-treated trypomastigotes and amastigotes of Trypanosoma cruzi.
Parasitology Research 100, 187–190.
Santos, A.O., Ueda-Nakamura, T., Dias-Filho, B.P., Veiga-Junior, V.F., Pinto, A.C.,
Nakamura, C.V., 2008. Effect of Brazilian copaiba oils on Leishmania
amazonensis. Journal of Ethnopharmacology 120, 204–208.
Schmid, W., 1975. The micronucleus test. Mutation Research 31, 9–15.
Sen, R., Bandyopadhyay, S., Dutta, A., Mandal, G., Ganguly, S., Saha, P., Chatterjee, M.,
2007. Artemisinin triggers induction of cell-cycle arrest and apoptosis in
Leishmania donovani promastigotes. Journal of Medical Microbiology 56, 1213–
1218.
Singh, N., Kaur, J., Kumar, P., Gupta, S., Singh, N., Ghosal, A., Dutta, A., Kumar, A.,
Tripathi, R., Siddiqi, M.I., Mandal, C., Dube, A., 2009. An orally effective
dihydropyrimidone (DHPM) analogue induces apoptosis-like cell death in
clinical isolates of Leishmania donovani overexpressing pteridine reductase 1.
Parasitology Research 105, 1317–1425.
Tiuman, T.S., Ueda-Nakamura, T., Cortez, D.A.G., Dias-Filho, B.P., Morgado-Díaz, J.A.,
Souza, W., Nakamura, C.V., 2005. Antileishmanial activity of parthenolide, a
sesquiterpene lactona isolated from Tanacetum parthenium. Antimicrobial
Agents Chemotherapy 49, 176–182.
Tiuman, T.S., Santos, A.O., Ueda-Nakamura, T., Dias Filho, B.P., Nakamura, C.V., 2011.
Recent advances in leishmaniasis treatment. International Journal of Infectious
Diseases, doi:10.1016/j.ijid.2011.03.021.
Ueda-Nakamura, T., Attias, M., Souza, W., 2001. Megasome biogenesis in Leishmania
amazonensis: a morphometric and cytochemical study. Parasitology Research
87, 89–97.
Vendrametto, M.C., Santos, A.O., Nakamura, C.V., Dias-Filho, B.P., Cortez, D.A.G.,
Ueda-Nakamura, T., 2010. Evaluation of antileishmanial activity of
eupomatenoid-5, a compound isolated from leaves of Piper regnellii var.
pallescens. Parasitology International 59, 154–158.
Adriana Oliveira dos Santos obtained her B.Sc. degree
in Biological Sciences in 2005 from the Universidade
Estadual de Maringá, Brazil. Currently she is a micro-
biology Ph.D. student under the supervision of Professor
Nakamura from the Universidade Estadual de Londrina,
Brazil, where she is studying biological activity of
medicinal plants from the Amazon rainforest, against
protozoan parasites. Her research interests are natural
products and their application to neglected diseases.Marco Antonio Costa graduated in Pharmacy and Bio-
chemistry at the Universidade Estadual de Maringá,
Brazil, in 1990. Currently, he is a microbiology Ph.D.
student under the supervision of Professor Nakamura at
the same university, where he is studying biological
activity of medicinal plants, against Candida sp. Too
currently he is an Assistant Professor at the Universid-
ade Estadual do Oeste do Paraná, and his research
interests are antimicrobial activity of natural products,
focusing on antifungal activity.Tania Ueda-Nakamura obtained her B.Sc. degree in
Pharmacy and Biochemistry in 1980 from the Univer-
sidade Estadual de Maringá, Brazil. In 2001, she received
her Ph.D. degree in Biophysics from the Universidade
Federal do Rio de Janeiro, and she undertook postdoc-
toral research on CERMAV – France, and currently she is
an Associate Professor of the Universidade Estadual de
Maringá. Her research interests are antiviral and anti-
protozoal activities of natural products.Benedito Prado Dias Filho received his B.Sc. degree in
Pharmacy and Biochemistry in 1973, from the Univer-
sidade Estadual de Ponta Grossa, Brazil, and in 1992, he
obtained his Ph.D. degree in Microbiology from the
Universidade Federal do Rio de Janeiro. Currently, he is a
Full Professor of the Universidade Estadual de Maringá.
His main interests are nanotechnology and antimicro-
bial activity of natural products, focusing on dermato-
phytes.Valdir Florêncio da Veiga Júnior obtained his B.Sc.
degree in Chemical Engineering in 1995 and the Ph.D.
degree in Chemistry in 2004 from the Universidade
Federal do Rio de Janeiro, Brazil. Currently, he is an
Associate Professor of the Universidade Federal do
Amazonas. His research interests are the chemistry of
natural products, focusing on medicinal plants of the
families Fabaceae, Burseraceae, and Lauraceae.Marli Miriam de Souza Lima is graduated in Pharmacy
at the Universidade Estadual de Maringá, Brazil, in 1989.
She obtained her Ph.D. degree in Polymer Physico-
Chemistry at the Université de Bordeaux I, France in
2002. She is currently professor at the Universidade
Estadual de Maringá in the department of Pharmacy.
Her research line is the development of drug release
systems biopolymer-based and it physico chemistry
caracterisation.Celso Vataru Nakamura graduated in Pharmacy and
Biochemistry at the Universidade Estadual de Maringá,
Brazil, in 1979. He obtained his Ph.D. degree in Micro-
biology at the Universidade Federal do Rio de Janeiro in
1992, and he undertook postdoctoral research on Bio-
physics, working with ultrastructural analysis of cellular
organelles from parasitic protozoa. Currently he is an
Associate Professor at the Universidade Estadual de
Maringá, and his research interests are the development
of new drugs from natural sources, focusing on anti-
microbial, antiprotozoal, and melanogenic activities.
